MX2019000219A - Forma de dosificación oral que contiene un revestimiento exterior de liberación rápida. - Google Patents

Forma de dosificación oral que contiene un revestimiento exterior de liberación rápida.

Info

Publication number
MX2019000219A
MX2019000219A MX2019000219A MX2019000219A MX2019000219A MX 2019000219 A MX2019000219 A MX 2019000219A MX 2019000219 A MX2019000219 A MX 2019000219A MX 2019000219 A MX2019000219 A MX 2019000219A MX 2019000219 A MX2019000219 A MX 2019000219A
Authority
MX
Mexico
Prior art keywords
dosage form
exterior coating
oral dosage
fast release
form containing
Prior art date
Application number
MX2019000219A
Other languages
English (en)
Inventor
Joseph Pulford Christopher
Original Assignee
Glaxosmithkline Consumer Healthcare Holdings Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Consumer Healthcare Holdings Us Llc filed Critical Glaxosmithkline Consumer Healthcare Holdings Us Llc
Publication of MX2019000219A publication Critical patent/MX2019000219A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Aspectos de la presente invención se refieren a una forma de dosificación oral que comprende un núcleo que contiene uno o más ingredientes activos y un recubrimiento exterior de rápida liberación; el recubrimiento exterior de rápida liberación incluye un polímero soluble en agua; un alcohol de sacárido o azúcar, o una combinación de los mismos, y un saborizante; el saborizante puede ser un refrescante templado que es liberado en la cavidad oral del usuario después de insertar la forma de dosificación en su boca.
MX2019000219A 2016-07-05 2017-07-05 Forma de dosificación oral que contiene un revestimiento exterior de liberación rápida. MX2019000219A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662358223P 2016-07-05 2016-07-05
PCT/US2017/040655 WO2018009500A1 (en) 2016-07-05 2017-07-05 Oral dosage form containing a fast release exterior coating

Publications (1)

Publication Number Publication Date
MX2019000219A true MX2019000219A (es) 2019-09-04

Family

ID=60892480

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000219A MX2019000219A (es) 2016-07-05 2017-07-05 Forma de dosificación oral que contiene un revestimiento exterior de liberación rápida.

Country Status (8)

Country Link
US (1) US11433037B2 (es)
EP (1) EP3481379A4 (es)
JP (1) JP2019524709A (es)
CN (1) CN109562075A (es)
BR (1) BR112019000282A2 (es)
CA (1) CA3029985A1 (es)
MX (1) MX2019000219A (es)
WO (1) WO2018009500A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220387328A1 (en) * 2021-06-04 2022-12-08 Glaxosmithkline Consumer Healthcare Holdings (Us) Llc Dosage form for nicotine replacement therapy

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4789546A (en) 1987-02-19 1988-12-06 Consumer Products Corp. Multiple-layer tablet with contrasting organoleptic characteristics
NZ233403A (en) * 1989-04-28 1992-09-25 Mcneil Ppc Inc Simulated capsule-like medicament
US5098715A (en) * 1990-12-20 1992-03-24 Burroughs Wellcome Co. Flavored film-coated tablet
AU1655595A (en) * 1994-04-29 1995-11-09 Mcneil-Ppc, Inc. Solid pharmaceutical dosage form containing flavored film coating
WO1997002273A1 (en) 1995-07-05 1997-01-23 The Procter & Gamble Company Warming compounds
US5807580A (en) * 1996-10-30 1998-09-15 Mcneil-Ppc, Inc. Film coated tablet compositions having enhanced disintegration characteristics
GB9707978D0 (en) 1997-04-21 1997-06-11 Procter & Gamble Throat soothing compositions
GB9707979D0 (en) 1997-04-21 1997-06-11 Procter & Gamble Confectionery compositions
AU7916798A (en) 1997-05-22 1998-12-11 Boots Company Plc, The Pharmaceutical compositions of flurbiprofen and burn-masking agent for treating sore throat
US6596298B2 (en) * 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
GB2350046B (en) 1999-05-20 2002-12-18 British Sugar Plc Edible compositions containing trehalose
DE19962251A1 (de) 1999-12-22 2001-09-06 Hermes Fabrik Pharm Praeparate Lutschtablette
US6780443B1 (en) 2000-02-04 2004-08-24 Takasago International Corporation Sensate composition imparting initial sensation upon contact
US6365215B1 (en) 2000-11-09 2002-04-02 International Flavors & Fragrances Inc. Oral sensory perception-affecting compositions containing dimethyl sulfoxide, complexes thereof and salts thereof
US20020119196A1 (en) * 2000-12-21 2002-08-29 Narendra Parikh Texture masked particles containing an active ingredient
AU4061702A (en) * 2001-05-15 2003-04-03 Mcneil-Ppc, Inc. Dip coating compositions containing starch or dextrin
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US20030072731A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing starch or dextrin
FR2832632B1 (fr) 2001-11-26 2004-04-23 Mane Fils V Capsule a solubilisation et liberation du contenu rapides
EP1555022B1 (en) 2002-09-21 2008-02-20 Shuyi Zhang Sustained release formulation of acetaminophen and tramadol
MX2007001611A (es) 2004-08-11 2007-04-10 Cadbury Adams Usa Llc Composiciones calidas y sistemas de liberacion de las mismas.
BRPI0518553A2 (pt) * 2004-12-13 2008-11-25 Mcneil Ppc Inc composiÇço farmacÊutica estÁvel, mÉtodo para estabilizaÇço de pelo menos um ingrediente farmaceuticamente ativo e mÉtodo de uso de celulose microcristalina silicificada
US20070275135A1 (en) 2005-02-09 2007-11-29 First Flavor, Inc. Taste sampling process and product
US20050196517A1 (en) 2005-02-14 2005-09-08 Mars, Incorporated Edible product having discrete regions with different heats of solution
JP2008537951A (ja) 2005-04-15 2008-10-02 フイルメニツヒ ソシエテ アノニム ホットフレーバーおよび皮膚感覚組成物
WO2006136196A1 (en) 2005-06-21 2006-12-28 V. Mane Fils Gellan seamless breakable capsule and process for manufacturing thereof
US20070036733A1 (en) 2005-08-12 2007-02-15 Takasago International Corp. (Usa) Sensation masking composition
WO2007126430A1 (en) 2005-12-23 2007-11-08 Cadbury Adams Usa Llc Compositions providing a heating sensation for oral or dermal delivery
US20070224258A1 (en) * 2006-03-22 2007-09-27 Bunick Frank J Dosage forms having a randomized coating
US20070231387A1 (en) 2006-04-04 2007-10-04 Luigi Levi Film-coated solid dosage forms
US20080131467A1 (en) * 2006-11-30 2008-06-05 Dennis Nelson Film-coated solid dosage form
US20080317677A1 (en) * 2007-06-22 2008-12-25 Szymczak Christopher E Laser Marked Dosage Forms
TWI547282B (zh) * 2007-07-02 2016-09-01 愛戴爾製藥股份有限公司 樂命達之口服分解錠劑組合物
KR20100119539A (ko) * 2007-12-10 2010-11-09 유란드, 인코포레이티드 다이펜하이드라민을 포함하는 경구 분해성 정제
ES2425356T3 (es) 2008-04-15 2013-10-14 Firmenich S.A. Composición sensorial de calidez
CN101612144A (zh) * 2008-05-19 2009-12-30 张书毅 含对乙酰氨基酚和曲马多的缓释制剂
EP2233134A1 (en) 2009-03-27 2010-09-29 McNeil AB Multi-portion intra-oral dosage form with organoleptic properties
EP2496219A1 (en) 2009-06-29 2012-09-12 McNeil-PPC, Inc. Pharmaceutical tablet containing a liquid filled capsule
CA2778273A1 (en) 2009-10-28 2011-05-12 Mcneil-Ppc, Inc. Fast dissolving/disintegrating coating compositions
BR112012030046A2 (pt) 2010-06-30 2016-08-09 Colgate Palmolive Co películas de camada múltipla para a liberação de aroma
RU2605299C2 (ru) * 2011-02-14 2016-12-20 Дзе Проктер Энд Гэмбл Компани Твердая единица дозирования в пленочной оболочке, содержащей мед
WO2012148432A1 (en) 2011-04-28 2012-11-01 Acme Specialty Products, Llc Taste masking compositions and edible forms thereof
US20130177646A1 (en) 2012-01-05 2013-07-11 Mcneil Ab Solid Nicotine-Comprising Dosage Form with Reduced Organoleptic Disturbance
US20140010768A1 (en) 2012-07-09 2014-01-09 Wild Flavors, Inc. Flavoring ingredient in oral compositions
US20140079740A1 (en) * 2012-08-02 2014-03-20 ClinPharm Support GmbH Oral transmucosal adminstration forms of s-ketamine

Also Published As

Publication number Publication date
US11433037B2 (en) 2022-09-06
RU2019102920A (ru) 2020-08-06
WO2018009500A1 (en) 2018-01-11
BR112019000282A2 (pt) 2019-04-16
RU2019102920A3 (es) 2020-08-28
EP3481379A4 (en) 2020-03-11
JP2019524709A (ja) 2019-09-05
CN109562075A (zh) 2019-04-02
US20180008562A1 (en) 2018-01-11
EP3481379A1 (en) 2019-05-15
CA3029985A1 (en) 2018-01-11

Similar Documents

Publication Publication Date Title
MX2020005892A (es) Formulacion de nicotina oral solida.
MX2017012877A (es) Composiciones gomosas de multicomponentes con nucleo suave.
MX2008011823A (es) Forma de dosificacion solida que contiene un agente activo de sabor encubierto.
PH12014501446A1 (en) Solid nicotine-comprising dosage form with reduced organoleptic disturbance
MX2021016109A (es) Metodos y composiciones particularmente para el tratamiento del trastorno por deficit de atencion.
NO20070887L (no) Kornformet farmasoytisk preparat med tidsbegrenset frigivelse for oral administrasjon, og intraoral hurtig desintegrerende tablett som inneholder preparatet
CL2012002115A1 (es) Una pastilla blanda que comprende nicotina, gelificante, platificante, edulcorante, agente liberador, conservante, saborizante, agua y es capaz de disolverse en la cavidad bucal en un periodo de 5 y 15 minutos; y proceso de preparacion.
MY181159A (en) Sublingual and buccal film compositions
WO2014159673A3 (en) Soft oral product
BR112012002817A8 (pt) Composições sublinguais e bucais em filme
SE1750679A1 (en) Nicotine-containing chewing gum compositions
IL282212A (en) Preparations containing macrocyclic lactones, methods for their preparation and the use of these preparations for the treatment of diseases due to parasites present in the tissues around the eye
WO2014138426A3 (en) Methods and compositions for reducing body fat and adipocytes
MX2013009703A (es) Precombinaciones de sabores para goma de mascar, metodos para elaborar precombinaciones de sabores, y composiciones de goma de mascar de las mismas.
PH12019500154A1 (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
MX2019000219A (es) Forma de dosificación oral que contiene un revestimiento exterior de liberación rápida.
IN2014DE00037A (es)
IL250852B (en) Periodontal preparation
WO2014027979A3 (en) Tablet formulations comprising tadalafil and dapoxetine
TR201909773T4 (tr) Nöropatilerin ve veya nöropatik ağrının tedavisine yönelik bir bileşim.
PH12016502059B1 (en) Fast dissolving granulate
MX2018010065A (es) Forma de dosificacion oral que comprende rifaximina en forma beta.
WO2014193498A3 (en) Meditation device
EA201491995A1 (ru) Пероральная лекарственная форма
PH12019500779A1 (en) Pharmaceutical complex preparation comprising amlodipine, losartan and rosuvastatin